Volume 16, Number 12—December 2010
CME ACTIVITY - Research
Pandemic (H1N1) 2009 Infection in Patients with Hematologic Malignancy
Catherine Liu
, Brian S. Schwartz, Snigdha Vallabhaneni, Michael Nixon, Peter V. Chin-Hong, Steven A. Miller, Charles Y. Chiu, Lloyd Damon, and W. Lawrence Drew
, Brian S. Schwartz, Snigdha Vallabhaneni, Michael Nixon, Peter V. Chin-Hong, Steven A. Miller, Charles Y. Chiu, Lloyd Damon, and W. Lawrence Drew
Table 1
Characteristics of hematologic malignancy patients with URTI or LRTI and pandemic (H1N1) 2009 virus, University of California, San Francisco, Medical Center, San Francisco, California, USA, June–December 2009*
| Characteristic | Total, n = 27 | URTI, n = 17 | LRTI, n = 10 | p value† |
|---|---|---|---|---|
| Median age, y (range) | 43 (5–83) | 33 (5–83) | 53 (29–80) | 0.04 |
| Male sex |
18 (67) |
10 (59) |
8 (80) |
0.24 |
| Underlying malignancy | ||||
| Acute lymphocytic leukemia | 6 (22) | 5 (29) | 1 (10) | 0.25 |
| Acute myelocytic leukemia | 5 (19) | 4 (24) | 1 (10) | 0.37 |
| Chronic lymphocytic leukemia | 1 (4) | 1 (6) | 0 | 0.63 |
| Lymphoma | 6 (22) | 2 (12) | 4 (40) | 0.11 |
| Multiple myeloma | 7 (26) | 4 (24) | 3 (30) | 0.52 |
| Other |
2 (7) |
1 (6) |
1 (10) |
0.61 |
| Hematopoietic cell transplant | 18 (67) | 12 (71) | 6 (60) | 0.44 |
| Allogeneic | 7 (39) | 4 (33) | 3 (50) | 0.43 |
| Graft-vs.-host disease | 6 (86) | 3 (75) | 3 (100) | 0.57 |
| Autologous | 11 (61) | 8 (67) | 3 (50) | 0.43 |
| Median time posttransplant, mo (range) |
12 (0.3–45) |
12 (3–45) |
11 (0.3–34) |
0.81 |
| Immunosuppressive medications | ||||
| Corticosteroid use | 7 (26) | 2 (12) | 5 (50) | 0.04 |
| T-/B-cell depleting agent |
4 (15) |
1 (6) |
3 (30) |
0.13 |
| Underlying concurrent conditions | ||||
| Obesity, body mass index >30 kg/m2 | 2 (7) | 0 | 2 (20) | 0.13 |
| Chronic lung disease | 5 (19) | 1 (6) | 4 (40) | 0.047 |
| Diabetes mellitus | 6 (22) | 1 (6) | 5 (50) | 0.015 |
| HIV infection | 2 (7) | 1 (6) | 1(10) | 0.61 |
*Values are given as no. (%) patients except as indicated. URTI, upper respiratory tract infection; LRTI, lower respiratory tract infection.
†p value represents statistical difference between comparison of values of patients with LRTI and URTI.
Page created: August 29, 2011
Page updated: August 29, 2011
Page reviewed: August 29, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.